Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
5.87
+0.17 (2.98%)
At close: Apr 14, 2026, 4:00 PM EDT
5.98
+0.11 (1.87%)
After-hours: Apr 14, 2026, 4:32 PM EDT
Company Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Minerva Neurosciences, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 1, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Remy Luthringer |
Contact Details
Address: 1500 District Avenue Burlington, Massachusetts 01803 United States | |
| Phone | 617 600 7373 |
| Website | minervaneurosciences.com |
Stock Details
| Ticker Symbol | NERV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001598646 |
| CUSIP Number | 603380205 |
| ISIN Number | US6033802058 |
| Employer ID | 26-0784194 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman and Chief Executive Officer |
| Geoffrey Robin Race F.C.M.A., M.B.A. | President |
| Frederick W. Ahlholm CPA | Senior Vice President, Chief Financial Officer and Secretary |
| Joseph Reilly | Senior Vice President and Chief Operating Officer |
| William B. Boni | Vice President of Investor Relations and Corporate Communications |
| Prof. Michael Davidson M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 6, 2026 | 8-K | Current Report |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 144 | Filing |
| Mar 31, 2026 | 144 | Filing |
| Mar 31, 2026 | 144 | Filing |
| Mar 19, 2026 | EFFECT | Notice of Effectiveness |
| Mar 11, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 11, 2026 | 10-K | Annual Report |
| Mar 11, 2026 | 8-K | Current Report |